Key Drivers
- Strong Liquidity
- Solid Margins
- Weak Cash Conversion
AIAI Summary
EW is no longer a turnaround but a premium-priced structural heart compounder, so it looks more like a hold than a buy unless TAVR keeps compounding and TMTT scales fast enough to justify ~44x earnings; otherwise, valuation and franchise concentration likely cap further re-rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Solid Margins
- •Weak Cash Conversion
EW has a strong balance sheet and solid profitability, but uneven cash conversion and a rich valuation make the stock look fairly priced to expensive.
Price Behavior
Key Price Behavior Insights:
- •Range-bound trading
- •Support holding
- •Breakout unconfirmed
Over the last month, EW has been range-bound and is constructive above $80, but it still needs a decisive breakout above about $84.2 to confirm stronger bullish momentum.
Rebounded sharply from $77.17 on 2026-05-11 to $81.38 on 2026-05-15 after a pullback
Sentiment & News
Key News Insights:
- •Revenue acceleration
- •Valve growth
- •Mixed valuation
Edwards Lifesciences delivered a strong Q1 beat with 16.7% sales growth, raised full-year guidance, and accelerating TAVR/TMTT momentum, though valuation signals remain mixed.
The quarter strengthens the growth case for Edwards Lifesciences, but investors may stay selective until valuation and margin expectations are clearer
Similar Companies in Healthcare
Other companies in the same sector with AI ratings